vs
Side-by-side financial comparison of Hologic (HOLX) and Teradyne (TER). Click either name above to swap in a different company.
Teradyne is the larger business by last-quarter revenue ($1.3B vs $1.0B, roughly 1.2× Hologic). Teradyne runs the higher net margin — 31.1% vs 17.1%, a 14.0% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (87.0% vs 2.5%). Over the past eight quarters, Teradyne's revenue compounded faster (32.6% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.
HOLX vs TER — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.3B |
| Net Profit | $179.1M | $398.9M |
| Gross Margin | 56.0% | 60.9% |
| Operating Margin | 22.6% | 36.9% |
| Net Margin | 17.1% | 31.1% |
| Revenue YoY | 2.5% | 87.0% |
| Net Profit YoY | -10.9% | — |
| EPS (diluted) | $0.79 | $2.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.0B | $1.1B | ||
| Q3 25 | $1.0B | $769.2M | ||
| Q2 25 | $1.0B | $651.8M | ||
| Q1 25 | $1.0B | $685.7M | ||
| Q4 24 | $1.0B | $752.9M | ||
| Q3 24 | $988.0M | $737.3M | ||
| Q2 24 | $1.0B | $729.9M |
| Q1 26 | — | $398.9M | ||
| Q4 25 | $179.1M | $257.2M | ||
| Q3 25 | $187.2M | $119.6M | ||
| Q2 25 | $194.9M | $78.4M | ||
| Q1 25 | $-17.4M | $98.9M | ||
| Q4 24 | $201.0M | $146.3M | ||
| Q3 24 | $178.6M | $145.6M | ||
| Q2 24 | $194.5M | $186.3M |
| Q1 26 | — | 60.9% | ||
| Q4 25 | 56.0% | 57.2% | ||
| Q3 25 | 55.6% | 58.4% | ||
| Q2 25 | 56.3% | 57.2% | ||
| Q1 25 | 37.5% | 60.6% | ||
| Q4 24 | 56.8% | 59.4% | ||
| Q3 24 | 56.4% | 59.2% | ||
| Q2 24 | 55.4% | 58.3% |
| Q1 26 | — | 36.9% | ||
| Q4 25 | 22.6% | 27.1% | ||
| Q3 25 | 22.6% | 18.9% | ||
| Q2 25 | 24.9% | 13.9% | ||
| Q1 25 | -0.7% | 17.6% | ||
| Q4 24 | 22.5% | 20.4% | ||
| Q3 24 | 23.3% | 20.6% | ||
| Q2 24 | 24.1% | 28.8% |
| Q1 26 | — | 31.1% | ||
| Q4 25 | 17.1% | 23.7% | ||
| Q3 25 | 17.8% | 15.5% | ||
| Q2 25 | 19.0% | 12.0% | ||
| Q1 25 | -1.7% | 14.4% | ||
| Q4 24 | 19.7% | 19.4% | ||
| Q3 24 | 18.1% | 19.8% | ||
| Q2 24 | 19.2% | 25.5% |
| Q1 26 | — | $2.53 | ||
| Q4 25 | $0.79 | $1.62 | ||
| Q3 25 | $0.84 | $0.75 | ||
| Q2 25 | $0.86 | $0.49 | ||
| Q1 25 | $-0.08 | $0.61 | ||
| Q4 24 | $0.87 | $0.89 | ||
| Q3 24 | $0.75 | $0.89 | ||
| Q2 24 | $0.82 | $1.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $241.9M |
| Total DebtLower is stronger | $2.5B | $0 |
| Stockholders' EquityBook value | $5.2B | — |
| Total Assets | $9.2B | $4.4B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $241.9M | ||
| Q4 25 | $2.4B | $293.8M | ||
| Q3 25 | $2.2B | $272.7M | ||
| Q2 25 | $1.9B | $339.3M | ||
| Q1 25 | $1.6B | $475.6M | ||
| Q4 24 | $2.0B | $553.4M | ||
| Q3 24 | $2.3B | $510.0M | ||
| Q2 24 | $2.4B | $421.9M |
| Q1 26 | — | $0 | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | — | ||
| Q4 25 | $5.2B | $2.8B | ||
| Q3 25 | $5.0B | $2.7B | ||
| Q2 25 | $4.8B | $2.8B | ||
| Q1 25 | $4.6B | $2.8B | ||
| Q4 24 | $4.8B | $2.8B | ||
| Q3 24 | $5.1B | $2.9B | ||
| Q2 24 | $5.0B | $2.7B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $9.2B | $4.2B | ||
| Q3 25 | $9.0B | $4.0B | ||
| Q2 25 | $8.8B | $3.8B | ||
| Q1 25 | $8.5B | $3.7B | ||
| Q4 24 | $8.7B | $3.7B | ||
| Q3 24 | $9.2B | $3.8B | ||
| Q2 24 | $8.9B | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $265.1M |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | 0.66× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $265.1M | ||
| Q4 25 | $229.9M | $281.6M | ||
| Q3 25 | $355.1M | $49.0M | ||
| Q2 25 | $343.3M | $182.1M | ||
| Q1 25 | $169.4M | $161.6M | ||
| Q4 24 | $189.3M | $282.6M | ||
| Q3 24 | $367.0M | $166.3M | ||
| Q2 24 | $405.8M | $216.1M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $218.8M | ||
| Q3 25 | $341.4M | $2.4M | ||
| Q2 25 | $330.5M | $131.7M | ||
| Q1 25 | $153.9M | $97.6M | ||
| Q4 24 | $172.5M | $225.2M | ||
| Q3 24 | $350.6M | $114.4M | ||
| Q2 24 | $385.3M | $171.2M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 20.2% | ||
| Q3 25 | 32.5% | 0.3% | ||
| Q2 25 | 32.3% | 20.2% | ||
| Q1 25 | 15.3% | 14.2% | ||
| Q4 24 | 16.9% | 29.9% | ||
| Q3 24 | 35.5% | 15.5% | ||
| Q2 24 | 38.1% | 23.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 5.8% | ||
| Q3 25 | 1.3% | 6.1% | ||
| Q2 25 | 1.3% | 7.7% | ||
| Q1 25 | 1.5% | 9.3% | ||
| Q4 24 | 1.6% | 7.6% | ||
| Q3 24 | 1.7% | 7.0% | ||
| Q2 24 | 2.0% | 6.1% |
| Q1 26 | — | 0.66× | ||
| Q4 25 | 1.28× | 1.09× | ||
| Q3 25 | 1.90× | 0.41× | ||
| Q2 25 | 1.76× | 2.32× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | 0.94× | 1.93× | ||
| Q3 24 | 2.05× | 1.14× | ||
| Q2 24 | 2.09× | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
TER
Segment breakdown not available.
